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To study the role of GBA variants in the risk for isolated REM sleep behavior disorder (iRBD) and
conversion to overt neurodegeneration.
Methods
A total of 4,147 individuals were included: 1,061 patients with iRBD and 3,086 controls. GBA was fully
sequenced using molecular inversion probes and Sanger sequencing. We analyzed the effects of GBA
variants on the risk of iRBD, age at onset (AAO), and conversion rates.
Results
GBA variants were found in 9.5% of patients with iRBD compared to 4.1% of controls (odds ratio, 2.45;
95% confidence interval [CI], 1.87–3.22; p = 1 × 10−10). The estimated OR for mild p.N370S variant
carriers was 3.69 (95% CI, 1.90–7.14; p = 3.5 × 10−5), while for severe variant carriers it was 17.55 (95%
CI, 2.11–145.9; p = 0.0015). Carriers of severeGBA variants had an average AAO of 52.8 years, 7–8 years
earlier than those with mild variants or noncarriers (p = 0.029). Of the GBA variant carriers with available
data, 52.5% had converted, compared to 35.6% of noncarriers (p = 0.011), with a trend for faster
conversion among severe GBA variant carriers. However, the results on AAO and conversion were based
on small numbers and should be interpreted with caution.
Conclusions
GBA variants robustly and differentially increase the risk of iRBD. The rate of conversion to neuro-
degeneration is also increased andmay be faster among severeGBA variant carriers, although confirmation
will be required in larger samples. Screening for RBD in healthy carriers ofGBA variants should be studied
as a potential way to identify GBA variant carriers who will develop a synucleinopathy in the future.
From the Department of Human Genetics (L.K., U.R., G.A.R., Z.G.-O.), Montreal Neurological Institute (L.K., J.A.R., U.R., E.L., F.A., R.B.P., G.A.R., Z.G.-O.), and Department of Neurology
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Isolated REM sleep behavior disorder (iRBD) can be considered
a prodromal synucleinopathy, because >80% of patients with
iRBD will eventually convert to an overt neurodegenerative
syndrome associated with α-synuclein accumulation—Parkinson
disease (PD), dementia with Lewy bodies (DLB), or multiple
system atrophy (MSA)1—with a conversion rate of about 6%
a year.2 For unknown reasons, while some patients with iRBD
convert rapidly, others can remain free from parkinsonism or
dementia for decades.3,4
Variants in the gene encoding for the lysosomal enzyme
glucocerebrosidase, GBA, are strong and relatively common
risk factors for PD5,6 and DLB,7 yet their role in MSA is
unclear.8–10 Patients with PD who carry GBA variants, as
a group, tend to have higher rates of nonmotor symptoms,
including REM sleep behavior disorder (RBD), cognitive
impairment, hyposmia, and autonomic dysfunction.11 GBA
variants can be classified as severe or mild based on the type of
Gaucher disease (GD) associated with the variant.12 Ac-
cordingly, patients with severeGBA variants have a higher risk
for PD, an earlier average age at onset (AAO),5 and faster
cognitive decline13,14 compared to patients with PD with mild
or no GBA variants.
Few studies with small sample size have examined the role
of GBA in iRBD, including studies of 69,15 171,16 and 265
patients with iRBD,15 all supporting an association between
GBA variants and iRBD but with different risk estimates. It
has been shown that in PD cohorts with available data on
probable RBD (pRBD), GBA variants are more frequent in
the group with pRBD.15 However, there are no accurate
estimates of the risk of iRBD among GBA variant carriers
and there have been no studies separately analyzing severe
and mild GBA variants. It is not clear whether GBA variants
affect the rate of conversion from iRBD to overt synuclei-
nopathies, as only 2 small sample size studies with contra-
dicting results examined this hypothesis. In one, there was
no association with the rate of conversion in 8 GBA variant
carriers with iRBD16; in the other, a faster conversion was
shown for 13 GBA variant carriers with iRBD compared to
noncarriers.17
In this study, we analyzed GBA variants in a large, multicenter
study including 1,061 patients with iRBD, more than double
the sample than all previous studies combined, and 3,086
controls, all of European origin. We further examined the
effects of severe vs mild GBA variants on risk of iRBD,
reported AAO of iRBD, and the potential effects on conver-
sion from iRBD to an overt neurodegenerative disease.
Methods
Population
The patient population included 1,061 individuals diagnosed
with iRBD with video-polysomnography according to the
International Classification of Sleep Disorders, version 2 or 3
criteria.18 The recruiting centers and the number of patients
from each center are detailed in table 1. Additional data were
available for subsets of samples, including reported AAO of
RBD (n = 594), age at diagnosis of iRBD (n = 599), eventual
phenoconversion to an overt neurodegenerative disease (data
available for n = 584, converted n = 218), and rate of phe-
noconversion (n = 217). The average follow-up period for
GBA carriers was 4.8 years and for noncarriers it was 4.1 years
(p = 0.22).
The data on these variables were collected in 2018. The
control population included a total of 3,086 individuals,
comprised of 1,317 in-house controls of European origin
(confirmed by principal component analysis using available
genome-wide association study [GWAS] data compared to
data fromHapMap v.3 and hg19/GRCh37) and an additional
1,769 previously published European controls in which GBA
was fully sequenced and all the variants were reported (table
e-1 details these controls and the reported GBA variants in
each of the articles; github.com/gan-orlab/GBA_RBD/).
The in-house controls had a mean age of 46.5 ± 15.0 years and
included 46.6% men, compared to 60.5 ± 9.9 and 81% men in
the patients, therefore when analyzing these populations,
adjustment for age and sex was performed (see Statistical
analysis and Results).
GBA sequencing and classification of
GBA variants
GBA was fully sequenced as described previously19 and the
full protocol is available upon request. In brief, we designed
molecular inversion probes (MIPs) targeting the coding se-
quence of GBA and performed next-generation sequencing
(NGS) post capture. Alignment, variant calling, and annota-
tions were done as previously described19 using a standard
pipeline. Exons 10 and 11 were also sequenced using Sanger
sequencing since the coverage of NGS of these exons was low.
Table e-2 (github.com/gan-orlab/GBA_RBD/) details the
probes used for the MIPs capture. Classification of GBA
variants as severe or mild was performed as described
Glossary
AAO = age at onset;CI = confidence interval;DLB = dementia with Lewy bodies;GCase = glucocerebrosidase;GD = Gaucher
disease; GWAS = genome-wide association study; iRBD = isolated REM sleep behavior disorder; MIP = molecular inversion
probe;MSA =multiple system atrophy;NGS = next-generation sequencing;OR = odds ratio; PD = Parkinson disease; pRBD =
probable REM sleep behavior disorder; RBD = REM sleep behavior disorder.
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previously5,12 based on the occurrence of these variants in the
severe (type II and type III) and mild (type I) forms of GD.
The p.E326K and p.T369M variants, which do not cause GD
but have a comparable risk as that of the p.N370S variants in
PD,20,21 were therefore included in the mild variant group.
Statistical analysis
To examine the association between GBA variants and risk of
iRBD and controls, we performed association tests (χ2 or
Fisher exact test), logistic regression adjusted for sex and age,
and burden tests. To examine the association of GBA variants
with risk of iRBD comparing all controls, we used χ2 or Fisher
exact tests since there were no available data on age and sex
from the controls collected from the literature to perform
adjusted logistic regression. We therefore also performed this
association using only our in-house European controls, for
which data on age and sex were available, using logistic re-
gression model adjusted for age and sex. Of note, having
younger controls may result in underestimation of the risk, as
some of the young controls with GBA variants may develop
iRBD or overt neurodegeneration in the future. Therefore, if
the statistical adjustment is not complete, the risk estimations
that were calculated could be slightly lower (i.e., false-positive
results are not likely; rather, underestimated risk is likely). We
Table 1 GBA variants in the participating centers
Center
GBA variant carriers, n
(%)/n total patients with
iRBD
GBA variants identified Conversion data
available for
patients, n
Conversion in GBA carriers:
condition (n converted)
Mild Severe Mild Severe







125 p.E326K–DLB (2), PD
(1), dementia (1)
p.T369M–PD (3),








Innsbruck, Austria 7 (9)/80 p.E326K–7 69 p.E326K–PD (1)






















Lille, France 5 (22)/23 p.E326K–2
p.N370S–2










Kessel, Germany 3 (11)/27 p.E326K–2
p.T369M–1
27 p.T369M–DLB (1)
Udine, Italy 6 (7)/83 p.E326K–2
p.N370S–2
p.T369M–1





















Abbreviations: DLB = dementia with Lewy bodies; iRBD = isolated REM sleep behavior disorder; MSA = multiple system atrophy; Parkinson disease.
Centers with noGBA variant carriers are excluded from the table: Geel, Belgium (n = 9); Nimes, France (n = 5);Marburg, Germany (n = 29);Munster, Germany (n
= 23); Cagliari, Italy (n = 28).
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also performed burden tests using the R package SKAT. As-
sociation with AAO and specific types ofGBA variants (severe
or mild) was tested using the nonparametric Kruskal-Wallis
test since the group of severe GBA variants included only 5
patients. The association with conversion was tested using
a χ2 test for the total number of conversions, and Kaplan-
Meier survival analysis was performed to examine the rate of
conversion. All statistical analyses were performed using R or
SPSS v24 (IBM, Armonk, NY).
Standard protocols approvals, registrations,
and patient consents
All study participants signed informed consent forms, and the
study protocol was approved by the institutional review boards.
Data availability
Anonymized data will be shared by request from any qualified
investigator.
Results
GBA variants are associated with increased risk of iRBD with
differential effects of severe and mild variants.
The variants in GBA identified in each of the participating
centers are detailed in table 1, with a total of 17 distinct
variants found in patients and controls (table 2). Table e-1
details the variants found in each of the previously published
control populations. Out of 1,061 patients with iRBD, 101
GBA variant carriers (9.5%) were identified, compared to 126
out of 3,086 (4.1%) controls (table 2; odds ratio [OR], 2.45;
95% confidence interval [CI], 1.87–3.22; p = 1 × 10−10). We
repeated this analysis using a logistic regression model ad-
justed for age and sex using the controls with available data (n
= 1,317), which yielded very similar results (OR, 2.12; 95%
CI, 1.34–3.36; p = 0.001). Burden tests using the R package
SKAT also yielded similar results (p = 2.6 × 10−6 using the in-
house controls and p = 1.7 × 10−12 using all controls). Similar
to previous observations in PD, different GBA variants have
different effects on the risk of iRBD. The mild p.N370S var-
iant was found in 20 patients with iRBD (1.9%) compared to
16 (0.5%) controls (OR, 3.69; 95% CI, 1.90–7.14; p = 3.5 ×
10−5), while severe variants (p.L444P, p.D409H, p.W291X,
p.H255Q, and p.R131L) were found in 6 (0.6%) patients with
iRBD and in 1 (p.L444P, 0.03%) control (OR, 17.55; 95% CI,
2.11–145.9; p = 0.0015). Of the 2 polymorphisms known to
be risk factors for PD, p.E326K and p.T369M, only p.E326K
was associated with iRBD (4.4% vs 1.5% in patients and
controls; OR, 3.2; 95% CI, 2.12–4.84; p = 6 × 10−9), and the
carrier frequency of p.T369M was only slightly elevated in
iRBD but not statistically significant (1.9% vs 1.7%; OR, 1.13;
95% CI, 0.68–1.89; p = 0.6). The carrier frequencies of the
p.N370S, p.E326K, and p.T369M variants in gnomAD
(gnomad.broadinstitute.org/) in the European population are
0.4%, 2.4%, and 1.9%, respectively, similar to the frequencies
in our controls.
Estimated AAO of iRBD may be affected by the
type of GBA variant
AAO as reported by the patients could be an unreliable esti-
mate and data were not available for all patients. Therefore,
the following results should be considered with caution.
Carriers of the severe GBA variants had an average AAO of
52.8 ±2.8 years (data were available for 5 out of 6 patients with
a severe GBA variant), carriers of all other variants had an
average AAO of 59.7 ± 9.6 years (data were available for 58
patients), and noncarriers of GBA variants had an average
AAO of 60.6 ± 9.9 years (data were available for 531 patients).
Because there were only 5 patients in the severe variants
group, the nonparametric Kruskal-Wallis test was performed,
demonstrating a possible association with the type of variant
(χ2 = 7.083, df = 3, p = 0.029), which will benefit from rep-
lication in a larger sample size.
DoGBA variants affect the rate of conversion of
iRBD to overt neurodegenerative diseases?
Data on conversion of iRBD was available for 59 GBA variant
carriers and 525 noncarriers of GBA variants. Of the GBA
variant carriers, 31 (52.5%) had converted, and in noncarriers
187 (35.6%) had converted (p = 0.011). Data on time from
iRBD diagnosis to phenoconversion or last follow-up was
available for 29 GBA variant carriers and for 276 noncarriers.
Kaplan-Meier survival analysis suggested that GBA variant
carriers progressed faster but the difference vs noncarriers of
GBA variants was not statistically significant (figure). When
severe GBA variant carriers were compared to mild GBA
carriers and noncarriers, a possible association was demon-
strated, as the Breslow test was statistically significant and the
Tarone-Ware test was at near statistical significance, while the
log-rank test did not reach statistical significance (figure;
Breslow p = 0.017, Tarone-Ware p = 0.051, log-rank p = 0.24).
Discussion
Our results confirm the association betweenGBA variants and
increased risk of iRBD and suggest that severe and mild GBA
variants have differential effects on risk, similar to previous
reports in PD.5 These results also suggest that patients with
iRBD with severe GBA variants may have earlier AAO and
may convert faster to overt neurodegenerative disease.
However, the results on AAO and conversion should be
considered as preliminary only and with caution, due to sev-
eral limitations discussed below.
Three previous small sample size studies have examined the
association between GBA variants and iRBD.15,16,22 Two of
these studies included full sequencing of the gene15,16 and the
third only examined 2 specific variants (p.N370S and
p.L444P).22 Due to their size, analyses of specific variants or
types of variants, such as severe or mild, were not possible.
The current study includes 2 of the previously published
cohorts15,22 and additional cohorts of European ancestry.
With the larger sample size accrued, we were able to
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demonstrate amuch larger risk in carriers of severeGBA variants.
Given the small numbers of these variants and the wide range of
the CIs, the risk estimates may be different in future, larger
studies. The current results are in line with previous results from
PD, which clearly demonstrated similar relationships between
severe and mild GBA variants and risk for PD.5 Previous studies
have also suggested that the type ofGBA variants may affect PD
progression,13,14 which is further supported by our preliminary
findings on AAO and conversion of iRBD.
In recent years it has been demonstrated that the coding
variants p.E326K and p.T369M, which do not cause GD, are
risk factors for PD.20,21,23 In DLB, the association between
p.E326K and risk for the disease is clear, yet it is still unclear
whether p.T369M is a risk factor for DLB. Only a few studies
that examined p.T369M in DLB have been performed and in
most of them there was no association. A multicenter study
that included over 700 patients with DLB reported lack of
association, and in a GWAS with over 1,700 patients with
DLB, only the p.E326K variant was reported to be associated
with the disease.7 Conversely, recent data from 556 patients
with DLB did suggest an association.24 The lack of association
in the current study in iRBDmay also provide further support
for lack of association of p.T369M with iRBD and DLB.
However, it is important to keep in mind that the association
of this variant with PD was only reported in much larger
studies20,21 due to its lower effect on risk compared to other
GBA variants. Only much larger studies can determine con-
clusively whether p.T369M is associated with iRBD and DLB.
There was a large difference between the frequency of
p.T369M in our in-house controls (2.7%) and the controls
from the literature (1.1%), perhaps due to population struc-
ture, but the combined frequency (1.7%) is comparable to
that seen in the gnomAD European population (1.9%), ren-
dering our results for this variant as likely unbiased.
Our study has several limitations. The possible association
between GBA variants and rate of conversion reported here,
Table 2 GBA variants in patients with isolated REM sleep behavior disorder (iRBD) and controls
GBA varianta
Patients with iRBD, n (%)
(n = 1,061)
All controls, n (%)
(n = 3,086)
In-house controls, n (%)
(n = 1,317)
Literature controls, n (%)
(n = 1,769)
Heterozygous
p.R2L 2 (0.2) 2 (0.06) 1 (0.08) 1 (0.06)
p.K79M — 1 (0.03) — 1 (0.06)
p.R131L 1 (0.1) — — —
p.Y212H 1 (0.1) — — —
p.N227S 1 (0.1) — — —
p.H255Q 1 (0.1) — — —
p.W291X 1 (0.1) — — —
p.E326K 47 (4.4) 45 (1.4) 18 (1.4) 27 (1.5)
p.T369M 20 (1.9) 54 (1.7) 35 (2.7) 19 (1.1)
p.N370S 20 (1.9) 16 (0.5) 10 (0.8) 6 (0.3)
p.W378G 2 (0.2) 1 (0.03) 1 (0.08) —
p.E388K — 3 (0.09) — 3 (0.17)
p.D409H 2 (0.2) — — —
p.L444P 1 (0.1) 1 (0.03) — 1 (0.06)
p.V460L — 2 (0.06) — 2 (0.11)
p.T482K — 1 (0.03) — 1 (0.06)
p.R502C 1 (0.1) — — —
Homozygous/compound heterozygous
p.E326K/p.T369M 1 (0.1) — — —
Total 101 (9.5) 126 (4.1) 65 (4.9) 61 (3.4)
a Variants nomenclature is according to the nomenclature typically used for GBA variants, of the active enzyme (497 amino acids) after the removal of the 39
amino acids of the leader peptide.
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although potentially interesting, should be taken with cau-
tion for several reasons. (1) The results include the cohort
from Montreal, in which it was previously reported that
GBA variants are associated with rate of conversion, but it
does not include the negative study from Barcelona (data
could not be shared). (2) The results are based on a small
number of variant carriers (4 patients with a severe GBA
variant, 25 with other GBA variants). Larger studies will be
required to determine conclusively whether GBA variants
are associated with the rate of phenoconversion. An addi-
tional potential limitation is that the measured duration
from age at diagnosis or iRBD to conversion might not
reflect the actual length of disease duration, as patients can
remain unaware for many years about their dream-
enactment behaviors, especially if they do not have a bed
partner or if they do not have very active or violent dreams.
The small number of severe GBA variants is also a limitation
in the risk analysis, as it created a wide CI. Since the effect of
severe vs mild variants is in line with previous studies in PD,
it is likely that these risk estimates of iRBD are overall
correct, yet the precise estimate might change in future,
larger studies.
The mechanisms underlying the association between GBA
variants, the enzyme encoded by GBA, glucocerebrosidase
(GCase), and the development of neurodegeneration are
unknown.11 Several mechanisms have been proposed, in-
cluding interaction of GCase substrates with α-synuclein,
which may lead to its accumulation,25 changes in the lyso-
somal membrane composition, which may lead to reduced
autophagy and mitophagy,26,27 accumulation of misfolded
GCase and endoplasmic reticulum stress,28 and others. The
association with iRBD may suggest that studying these
mechanisms in nondopaminergic neuronal models that are
involved in RBD could lead to new discoveries and better
understanding of these potential mechanisms.
Our results demonstrate that GBA variants are associated
with increased risk of iRBD. These results may also suggest
that severe and mild GBA variants may have differential
effects on the risk, and possibly on AAO, of iRBD and its
conversion to overt neurodegenerative disease. Due to the
limitations mentioned above, the latter associations should
be considered as preliminary with additional, larger studies
on GBA in iRBD required to confirm or refute them. One
important implication of the association between GBA var-
iants and iRBD is the possibility to perform screening for
iRBD in healthy GBA variant carriers. This may allow for
even earlier detection of prodromal neurodegeneration and
could be especially useful when home detection of iRBD will
be made possible.
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Montréal, Canada
Major role in the acquisition








Major role in the acquisition








Major role in the acquisition




Neurology.org/N Neurology | Volume 95, Number 8 | August 25, 2020 e1015
References
1. Hogl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neu-
rodegeneration: an update. Nat Rev Neurol 2018;14:40–55.
2. Postuma RB, Iranzo A, HuM, et al. Risk and predictors of dementia and parkinsonism
in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 2019;142:
744–759.
3. Yao C, Fereshtehnejad SM, Dawson BK, et al. Longstanding disease-free survival in
idiopathic REM sleep behavior disorder: is neurodegeneration inevitable? Parkin-
sonism Relat Disord 2018;54:99–102.
4. Iranzo A, Stefani A, Serradell M, et al. Characterization of patients with longstanding
idiopathic REM sleep behavior disorder. Neurology 2017;89:242–248.
5. Gan-Or Z, Amshalom I, Kilarski LL, et al. Differential effects of severe vs mild GBA
mutations on Parkinson disease. Neurology 2015;84:880–887.
6. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase
mutations in Parkinson’s disease. N Engl J Med 2009;361:1651–1661.
7. Nalls MA, Duran R, Lopez G, et al. A multicenter study of glucocerebrosidase
mutations in dementia with Lewy bodies. JAMA Neurol 2013;70:727–735.
8. Mitsui J, Matsukawa T, Sasaki H, et al. Variants associated with Gaucher disease in
multiple system atrophy. Ann Clin Transl Neurol 2015;2:417–426.
9. Sailer A, Scholz SW, Nalls MA, et al. A genome-wide association study in multiple
system atrophy. Neurology 2016;87:1591–1598.
10. Sklerov M, Kang UJ, Liong C, et al. Frequency of GBA variants in autopsy-proven
multiple system atrophy. Mov Disord Clin Pract 2017;4:574–581.
11. Gan-Or Z, Liong C, Alcalay RN. GBA-associated Parkinson’s disease and other
synucleinopathies. Curr Neurol Neurosci Rep 2018;18:44.
12. Beutler E, Gelbart T, Scott CR. Hematologically important mutations: Gaucher
disease. Blood Cell Mol Dis 2005;35:355–364.
13. Cilia R, Tunesi S, Marotta G, et al. Survival and dementia in GBA-associated Par-
kinson’s disease: the mutation matters. Ann Neurol 2016;80:662–673.
14. Liu G, Boot B, Locascio JJ, et al. Specifically neuropathic Gaucher’s mutations ac-
celerate cognitive decline in Parkinson’s. Ann Neurol 2016;80:674–685.
15. Gan-Or Z, Mirelman A, Postuma RB, et al. GBA mutations are associated with rapid
eye movement sleep behavior disorder. Ann Clin Transl Neurol 2015;2:941–945.
16. Gamez-Valero A, Iranzo A, Serradell M, et al. Glucocerebrosidase gene variants are
accumulated in idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord
2018;50:94–98.
17. Honeycutt L, Montplaisir JY, Gagnon JF, et al. Glucocerebrosidase mutations and
phenoconversion of REM sleep behavior disorder to parkinsonism and dementia.
Parkinsonism Relat Disord 2019;65:230–233.
18. Hogl B, Stefani A. REM sleep behavior disorder (RBD): update on diagnosis and
treatment. Somnologie 2017;21:1–8.
19. Ruskey JA, Zhou S, Santiago R, et al. The GBA p.Trp378Gly mutation is a probable
French-Canadian founder mutation causing Gaucher disease and synucleinopathies.
Clin Genet 2018;94:339–345.
20. Blauwendraat C, Bras JM, Nalls MA, et al. Coding variation in GBA explains the
majority of the SYT11-GBA Parkinson’s disease GWAS locus. Mov Disord 2018;33:
1821–1823.
21. Mallett V, Ross JP, Alcalay RN, et al. GBA p.T369M substitution in Parkinson disease:
polymorphism or association? A meta-analysis. Neurol Genet 2016;2:e104.
22. Barber TR, Lawton M, Rolinski M, et al. Prodromal parkinsonism and neurodegen-
erative risk stratification in REM sleep behavior disorder. Sleep 2017;40.
23. Berge-Seidl V, Pihlstrom L, Maple-Grodem J, et al. The GBA variant E326K is
associated with Parkinson’s disease and explains a genome-wide association signal.
Neurosci Lett 2017;658:48–52.
24. Gan-Or Z, Alcalay RN, Makarious MB, et al. Classification of GBA variants and their
effects in synucleinopathies. Mov Disord 2019;34:1581–1582.
25. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-
synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146:
37–52.
26. Gan-Or Z, Dion PA, Rouleau GA. Genetic perspective on the role of the autophagy-
lysosome pathway in Parkinson disease. Autophagy 2015;11:1443–1457.
27. Osellame LD, Duchen MR. Defective quality control mechanisms and accumulation
of damaged mitochondria link Gaucher and Parkinson diseases. Autophagy 2013;9:
1633–1635.
28. Ron I, Rapaport D, Horowitz M. Interaction between parkin and mutant glucocer-
ebrosidase variants: a possible link between Parkinson disease and Gaucher disease.








Major role in the acquisition








Major role in the acquisition









major role in the acquisition
of data, drafted the
manuscript for intellectual
content
e1016 Neurology | Volume 95, Number 8 | August 25, 2020 Neurology.org/N
DOI 10.1212/WNL.0000000000010042
2020;95;e1008-e1016 Published Online before print June 26, 2020Neurology 
Lynne Krohn, Jennifer A. Ruskey, Uladzislau Rudakou, et al. 
 variants in REM sleep behavior disorder: A multicenter studyGBA




including high resolution figures, can be found at:
References
 http://n.neurology.org/content/95/8/e1008.full#ref-list-1





Dementia with Lewy bodies
following collection(s): 




its entirety can be found online at:




Information about ordering reprints can be found online:
ISSN: 0028-3878. Online ISSN: 1526-632X.
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Print
1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2020 The Author(s). Published by 
® is the official journal of the American Academy of Neurology. Published continuously sinceNeurology 
